IL17A and systemic lupus erythematosus: In a study involving CD4+ T cells isolated from patients with SLE and RA, activation in the presence or absence of Canagliflozin demonstrated that Canagliflozin effectively inhibited the production of IL-2, IFN-γ, interleukin-17 (IL-17), and TNF cytokines (85).